The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
<h4>Background</h4>Interstitial lung diseases (ILDs) are chronic, parenchymal lung diseases with a variable clinical course and a poor prognosis. Within various clinical courses, acute exacerbation (AE) is a devastating condition with significant morbidity and high mortality. The aim of...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0255365 |
id |
doaj-3ba546534f9944649dc737960238aea9 |
---|---|
record_format |
Article |
spelling |
doaj-3ba546534f9944649dc737960238aea92021-08-03T04:31:44ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01167e025536510.1371/journal.pone.0255365The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.Jae Ha LeeJi Hoon JangJin Han ParkHang-Jea JangChan Sun ParkSunggun LeeSeong-Ho KimJi Yeon KimHyun Kuk Kim<h4>Background</h4>Interstitial lung diseases (ILDs) are chronic, parenchymal lung diseases with a variable clinical course and a poor prognosis. Within various clinical courses, acute exacerbation (AE) is a devastating condition with significant morbidity and high mortality. The aim of this study was to investigate the role of interleukin-6 (IL-6) to predict AE and prognosis in patients with ILD.<h4>Methods</h4>Eighty-three patients who were diagnosed with ILD from 2016 to 2019 at the Haeundae Paik Hospital, Busan, South Korea, were included and their clinical data were retrospectively analyzed.<h4>Results</h4>The median follow-up period was 20 months. The mean age was 68.1 years and 65.1% of the patients were men with 60.2% of patients being ever-smokers. Among ILDs, idiopathic pulmonary fibrosis was the most common disease (68.7%), followed by connective tissue disease-associated ILD (14.5%), cryptogenic organizing pneumonia (9.6%), and nonspecific interstitial pneumonia (6.0%). The serum levels of IL-6 were measured at diagnosis with ILD and sequentially at follow-up visits. During the follow-ups, 15 (18.1%) patients experienced an acute exacerbation (AE) of ILD and among them, four (26.7%) patients died. In the multivariable analysis, high levels of IL-6 (OR 1.014, 95% CI: 1.001-1.027, p = 0.036) along with lower baseline saturations of peripheral oxygen (SpO2) were independent risk factors for AE. In the receiver operating characteristic curve analysis, the area under the curve was 0.815 (p < 0.001) and the optimal cut-off value of serum IL-6 to predict AE was 25.20 pg/mL with a sensitivity of 66.7% and specificity of 80.6%. In the multivariable Cox analysis, a high level of serum IL-6 (HR 1.007, 95% CI: 1.001-1.014, p = 0.018) was only an independent risk factor for mortality in ILD patients.<h4>Conclusions</h4>In our study, a high level of serum IL-6 is a useful biomarker to predict AE and poor prognosis in patients with ILD.https://doi.org/10.1371/journal.pone.0255365 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jae Ha Lee Ji Hoon Jang Jin Han Park Hang-Jea Jang Chan Sun Park Sunggun Lee Seong-Ho Kim Ji Yeon Kim Hyun Kuk Kim |
spellingShingle |
Jae Ha Lee Ji Hoon Jang Jin Han Park Hang-Jea Jang Chan Sun Park Sunggun Lee Seong-Ho Kim Ji Yeon Kim Hyun Kuk Kim The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases. PLoS ONE |
author_facet |
Jae Ha Lee Ji Hoon Jang Jin Han Park Hang-Jea Jang Chan Sun Park Sunggun Lee Seong-Ho Kim Ji Yeon Kim Hyun Kuk Kim |
author_sort |
Jae Ha Lee |
title |
The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases. |
title_short |
The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases. |
title_full |
The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases. |
title_fullStr |
The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases. |
title_full_unstemmed |
The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases. |
title_sort |
role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2021-01-01 |
description |
<h4>Background</h4>Interstitial lung diseases (ILDs) are chronic, parenchymal lung diseases with a variable clinical course and a poor prognosis. Within various clinical courses, acute exacerbation (AE) is a devastating condition with significant morbidity and high mortality. The aim of this study was to investigate the role of interleukin-6 (IL-6) to predict AE and prognosis in patients with ILD.<h4>Methods</h4>Eighty-three patients who were diagnosed with ILD from 2016 to 2019 at the Haeundae Paik Hospital, Busan, South Korea, were included and their clinical data were retrospectively analyzed.<h4>Results</h4>The median follow-up period was 20 months. The mean age was 68.1 years and 65.1% of the patients were men with 60.2% of patients being ever-smokers. Among ILDs, idiopathic pulmonary fibrosis was the most common disease (68.7%), followed by connective tissue disease-associated ILD (14.5%), cryptogenic organizing pneumonia (9.6%), and nonspecific interstitial pneumonia (6.0%). The serum levels of IL-6 were measured at diagnosis with ILD and sequentially at follow-up visits. During the follow-ups, 15 (18.1%) patients experienced an acute exacerbation (AE) of ILD and among them, four (26.7%) patients died. In the multivariable analysis, high levels of IL-6 (OR 1.014, 95% CI: 1.001-1.027, p = 0.036) along with lower baseline saturations of peripheral oxygen (SpO2) were independent risk factors for AE. In the receiver operating characteristic curve analysis, the area under the curve was 0.815 (p < 0.001) and the optimal cut-off value of serum IL-6 to predict AE was 25.20 pg/mL with a sensitivity of 66.7% and specificity of 80.6%. In the multivariable Cox analysis, a high level of serum IL-6 (HR 1.007, 95% CI: 1.001-1.014, p = 0.018) was only an independent risk factor for mortality in ILD patients.<h4>Conclusions</h4>In our study, a high level of serum IL-6 is a useful biomarker to predict AE and poor prognosis in patients with ILD. |
url |
https://doi.org/10.1371/journal.pone.0255365 |
work_keys_str_mv |
AT jaehalee theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jihoonjang theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jinhanpark theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT hangjeajang theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT chansunpark theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT sunggunlee theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT seonghokim theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jiyeonkim theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT hyunkukkim theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jaehalee roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jihoonjang roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jinhanpark roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT hangjeajang roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT chansunpark roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT sunggunlee roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT seonghokim roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jiyeonkim roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT hyunkukkim roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases |
_version_ |
1721224055376314368 |